logo
Protest continues as Gulf World dolphin removal is delayed

Protest continues as Gulf World dolphin removal is delayed

Yahoo4 days ago

PANAMA CITY BEACH, Fla. (WMBB) – U.S. Congressman Neal Dunn's office reported that seven bottlenose dolphins were cleared for removal from Gulf World on Friday. They were expected to be removed by Saturday.
A video shows that preparations for the dolphin's removal are underway.
Protesters camped outside Gulf World all Friday night, and say they haven't seen the dolphins leave yet.
Protestors say they just want the dolphins removed, but not to another facility owned by the Dolphin Company.
Gulf World Marine Park dolphins potentially being moved within the next 24 hours
The park reportedly has 11 dolphins left.
According to the latest update from Neal Dunn's office, there are still four living rough-tooth dolphins without permits for removal.
'We are begging, begging, begging. Please. We know that you guys have a permit to get these Southern Bottlenose dolphins out. There are still four rusty dolphins in there. We need all the dolphins. Like, we are concerned for the safety of every single living creature there,' protester Jamie Marghany said.
After hearing confirmation that a fifth dolphin died on Wednesday, protestors want state-level action.
'It's inhumane. It's animal abuse on the highest level. And I am so sad that our Governor Ron DeSantis, our attorney general, has not done anything to step up and save these animals,' protester Cheryl Cargile said.
The park closed unexpectedly on Wednesday and is said to remain closed until June 3rd. However, tickets were still available for purchase online the day before.
Now, ticket-buyers are struggling to get a refund.
'We went online and Tuesday to look for the tickets. We put it up here because I've always wanted to run the Dolphins here, and it shows open not to fortnightly. So we've been coming down through here, and it shows daily, and it shows right here on their little sign, their little advertisement of everything. The people that's beside me from Georgia bought their tickets online they bought their tickets online. But when you go to call my brother Justine, they hang the phone number so they won't even speak,' Gulf World customer Amy Killian said.
Gulf World employees were on-site, but did not provide refunds. Protesters believe Gulf World is hiding what conditions the animals are living in.
'We know for a fact that they are Photoshopping pictures because we had someone go in the same day that they posted a photo. Theirs is perfectly blue, clear water, and the actual photo is green. So the dolphins all have abnormalities and issues. They're shocking with granular chemicals because the numbers are broken. It's just not a good situation,' Marghany said.
AFib awareness: Stroke risks & advanced treatment options
They believe Gulf World is leaving a negative impact on tourists visiting Panama City Beach.
'I have a two-year-old grandbaby that's still crying, wanting to go in there, baby, we can't go in there, honey. They're not alive. And how do you explain that to a two-year-old?' Killian added.
The fight isn't just for the dolphins. Protestors want all of the animals to be removed from Gulf World.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Patients With HS, Obesity Report Improvements With GLP-1 RAs
Patients With HS, Obesity Report Improvements With GLP-1 RAs

Medscape

time18 minutes ago

  • Medscape

Patients With HS, Obesity Report Improvements With GLP-1 RAs

In a survey of 22 patients with hidradenitis suppurativa (HS), more than two thirds reported symptom improvement after treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs). METHODOLOGY: Researchers conducted a cross-sectional survey of 22 adults (average age, 45 years; 90.9% women) with HS who were treated with GLP-1 RAs at the University of Pennsylvania's Dermatology Department between January 2019 and August 2024. Most participants were non-Hispanic (90.9%), 54.5% were Black, and 36.4% were White; 89.5% were classified as overweight or having obesity. GLP-1 RAs prescriptions were semaglutide (40.9%), tirzepatide (36.4%), dulaglutide (18.2%), or liraglutide (4.5%), with an average treatment duration of 17 months (range, 2-108 months). Primary outcomes were HS severity and quality of life. TAKEAWAY: Most participants (77.3%) achieved weight loss averaging 31 lb; 68.2% reported improvement in HS-specific health, while 31.8% reported no change in their condition. Patient-reported symptom improvements included reduced flares (61.9%), new lesions (66.7%), pain (52.4%), drainage (61.9%), itch (47.6%), and odor (42.9%). Common side effects included gastrointestinal symptoms, allergic reactions, headaches, menstrual spotting, and appetite suppression. Nearly 60% of patients reported that HS had less impact on their daily activities, with the same percentage stating they would recommend GLP-1 RAs to other patients. IN PRACTICE: 'These data suggest GLP-1 RAs may play an important adjunctive role in the treatment of HS, particularly given the high prevalence of obesity and diabetes in the HS population,' the study authors wrote. 'Randomized controlled studies with robust patient and dermatologist-reported endpoints,' they added, 'are needed to confirm these findings and establish clinical guidelines for use of GLP-1 RAs' in HS. SOURCE: The study was led by Radhika Gupta, BA, University of Pennsylvania, Philadelphia. It was published online on May 29 in JAAD International . LIMITATIONS: Study limitations included small size, lack of clinician assessment, high nonresponse rate, and potential recall bias. DISCLOSURES: The study received funding through a philanthropic gift for HS research. Gupta disclosed being a consultant for Cabaletta Bio. One author reported receiving research funding from Amgen, Boehringer Ingelheim, Cabaletta Bio, and InflaRx. Another author reported being a consultant for Sonoma Biotherapeutics, and the fourth author reported being a consultant for Vertex Pharmaceuticals.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store